source
- Azalea Therapeutics wins Endpoints 11 award, combines gene editing with CAR-T and raises $82 millionAzalea Therapeutics was named the winner of the Endpoints 11 2026 competition, highlighting its innovative approach in the biotech space. The company’s platform merges precise gene‑editing techniq…
- Novo signs $1.3 billion deal with Nanexa to add long-acting injectables for obesity and diabetesNovo has entered a licensing agreement with Nanexa, valued at about 1.17 billion euros, to use Nanexa’s PharmaShell platform for its obesity and type‑2 diabetes medicines. The PharmaShell technolo…